Cardiomyocyte preparation as well as preparation method and application thereof

Abstract

The invention provides a cardiomyocyte preparation. The cardiomyocyte preparation comprises cardiomyocytes and fibroblasts, differentiated from pluripotent stem cells, wherein the concentration of thecardiomyocytes in the cardiomyocyte preparation is 0.75*10<7>-1.0*10<9> cell/mL, and the content of the cardiomyocytes is higher than 80% while the content of fibroblasts is not higher than 20%. Thecardiomyocyte preparation provided by the embodiment can effectively improve the ejection fraction of the heart and fractional shortening of the left ventricle, increase thickness of the inner wall ofthe left ventricle and enhance the cardiac function; the invention further provides a preparation method and an application of the cardiomyocyte preparation to treatment of heart failure. The preparation method of the cardiomyocyte preparation comprises simple steps, has high repetition rate, and is suitable for large-scale production.

Description

technical field [0001] The invention relates to the technical field of cell preparations, in particular to a cardiomyocyte preparation and a preparation method and application thereof. Background technique [0002] Heart failure is a pathological phenomenon of cardiac insufficiency caused by the development of various heart diseases to the late stage. It is a group of clinical syndromes that impair ventricular filling or ejection ability due to the malfunction of the systolic or diastolic function of the heart. The clinical manifestation is ejection of blood. Fractional and ventricular short-axis shortening rates decreased, myocardial wall pressure increased, cardiac chamber diameters increased, and left ventricular diastolic and systolic volumes increased. [0003] ACC / AHA divides heart failure into four stages: A, B, C, and D. Stages A and B refer to patients who lack early symptoms of heart failure, but have risk factors or cardiac abnormalities, including cardiac morphol...

AI Technical Summary

Problems solved by technology

[0005] The current methods of treating heart failure (heart failure) mainly use chemical drugs to play the role of treating heart failure by reducing the activity of the neuroendocrine system, blocking or improving the adverse effects caused by excessive excitation of AT1R, or eliminating the retention of water and sodium in heart failure. However, clinical practice shows that these chemical drugs have different adverse reactions in the treatment of heart failure, such as hypotension or deterioration of renal function, etc.

[0006] With the development of stem cell technology, scholars in this field are committed to studying how to treat end-stage heart failure caused by various heart diseases through stem cell transplantation. stem cells are tumorigenic and not suitable for clinical research and treatment

Images